Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Zydus gets USFDA nod...

    Zydus gets USFDA nod for phase II trials of liver drug

    Written by supriya kashyap kashyap Published On 2017-02-24T11:32:07+05:30  |  Updated On 24 Feb 2017 11:32 AM IST

    New Delhi : Drug firm Zydus Cadila said the US health regulator has approved the group's plans to initiate phase II clinical trials of Saroglitazar Magnesium in patients suffering from a certain liver disease.


    "The United States Food and Drug Administration (USFDA) has approved the group's plans to initiate a phase II clinical trial of Saroglitazar Magnesium (Mg) in patients with primary biliary cholangitis (PBC) of the liver," Zydus Cadila said in a statement.


    This trial will evaluate Saroglitazar Magnesium 2mg and 4mg vs Placebo, it added.


    Commenting on the development, Zydus Cadila Chairman and MD Pankaj R Patel said: "We are very thankful to the USFDA for their timely and useful feedback on the clinical trial designs of Saroglitazar Mg in patients with PBC."


    This development underlines the group's commitment to bridging unmet healthcare needs with innovative therapies, he added.


    Primary Biliary Cholangitis is a liver disease, caused due to progressive destruction of the bile ducts in the liver which leads to reduction of bile flow a condition referred to as cholestasis, Zydus Cadila said.


    Progression of PBC leads to symptoms of cirrhosis like yellowing of the skin, swelling of legs and feet, ascites, internal bleeding and thinning of the bones, it added.


    Shares of Cadila Healthcare, the listed entity of the group, were trading at Rs 430.50 per scrip on BSE, down 0.93 per cent from its previous close.

    Biliary CholangitisHealthcareliver drugPankaj R PatelUSFDAzydus
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok